ARCHIVES

Phase IIb Trial of Vintafolide-Docetaxel Combination Meets Primary Endpoint of Progression-Free Survival

This article is from The Cancer Letter archive.

Vol. 37 No. 3 | March 28, 2014

Download PDF Visit The Full Archive

Related Articles

In Brief: Bernard Fisher Professorship Endowed By ICI Pharma; Brady Wins RSNA Medal

January 5, 1990

Six NY Institutes Form Cancer Vaccine Collaboration

November 8, 2002

Klausner Unveils New NCI Structure, Aims To Change Institute’s “Ethos”

August 11, 1995

In Brief: NIDR, NCI award $2.8 Million In Grants For Oral Cancer research Centers

October 4, 1996

In Brief: Harkin Proposes To Add Another $400 Million To NCU Budget, Money To Come Forom Defense

July 26, 1991

RFAs: Patient Outcomes “5-A-Day” Program

April 10, 1992